The company has developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from various sample types. With a strong IP portfolio, Rosetta Genomics has launched four commercial oncology tests globally through partnerships and its own efforts in the US. They are focused on developing next-generation diagnostic tests for personalized medicine.